Kyle Jacoby

Company: Kanvas Biosciences

Job title: Vice President

Seminars:

KAN-001, a Complex Consortium Live Biotherapeutic Product to Augment Cancer Therapy 11:30 am

From FMTs to LBPs: A reverse translational approach to creating an optimized and sustainable therapy to augment patients’ immune systems and response to cancer immune checkpoint therapy KAN-001 optimization and preclinical testing KAN-001 strains in patients: assessing existing KAN-001 strain-level clinical engraftment data de-risks developmentRead more

day: Conference Day One, Track Two, AM